Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 19Lung Neoplasms 5Wilms Tumor 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Central Nervous System Neoplasms 2Xanthogranuloma, Juvenile 1The Diagnosis Was ALK Positive NSCLC 1Solid Tumors 1Solid Tumor 1Solid Advanced Tumor 1Sarcoma, Ewing 1Neoplasms 1Melanoma 1Histiocytic Sarcoma 1Carcinoma 1Brain Neoplasms 1ALK-positive Advanced NSCLC 1

Interventions

ensartinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Solid Advanced Tumor × ensartinib × Clear all
NCT07448116 2026-03-04

Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.

Betta Pharmaceuticals Co., Ltd.

Phase 1/2 Recruiting
164 enrolled

Solid Advanced Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡